Press Releases Indaptus Therapeutics, Inc.

Equities

INDP

US45339J1051

Delayed Nasdaq Other stock markets 09:49:22 2024-04-30 am EDT			5-day change	1st Jan Change
2.185 ^USD	+2.98%		-12.25%	+24.15%

Mar. 14	Top Premarket Gainers	MT
Mar. 13	Indaptus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting	Apr. 11	AQ
Indaptus Therapeutics : April 2024 April 2024 Investor Presentation	Apr. 07	PU
Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference	Mar. 28	AQ
Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting	Mar. 25	AQ
Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024	Mar. 18	AQ
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update	Mar. 13	AQ
Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort	Mar. 04	AQ
Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor Conference	Feb. 15	AQ
Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels	Feb. 08	AQ
European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform Technology	Jan. 04	AQ
Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update	Nov. 06	AQ
Indaptus Therapeutics’ Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 Study	Nov. 06	AQ
Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting	23-10-31	AQ
Indaptus Therapeutics to Present at the LD Micro Main Event XVI	23-09-27	AQ
Registration Is Now Open For Tribe Public’s Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics’ CEO On Friday, September 29, 2023	23-09-26	AQ
Indaptus Therapeutics Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20	23-09-19	AQ
Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference	23-09-06	AQ
Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update	23-08-14	AQ
Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20	23-08-10	AQ
Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical Officer	23-08-07	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Indaptus Therapeutics, Inc.

Equities

INDP

US45339J1051

Press Releases

Filters